Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 10, 2022
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulatorsLaura M Tsujikawa, Olesya A Kharenko, Stephanie C Stotz, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2021
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled TrialKamyar Kalantar-Zadeh, Gregory G Schwartz, Stephen J Nicholls, et al.
Biomedicines|April 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In VitroDean Gilham, Audrey L Smith, Li Fu, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 24, 2019
ApoE4 Alters ABCA1 Membrane Trafficking in AstrocytesVarun Rawat, Shaowei Wang, Jian Sima, et al.
Alzheimer'S Research & Therapy|June 24, 2022
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeysSasan D Noveir, Bilal E Kerman, Haotian Xian, et al.
American Journal of Preventive Cardiology|August 30, 2022
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver diseasePeter P Toth, Gregory G Schwartz, Stephen J Nicholls, et al.
Atherosclerosis|December 1, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cellsSylwia Wasiak, Laura M Tsujikawa, Emily Daze, et al.
Atherosclerosis|October 1, 2019
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular diseaseMathias Haarhaus, Kausik K Ray, Stephen J Nicholls, et al.
Clinical Epigenetics|November 11, 2020
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetesSylwia Wasiak, Kim E Dzobo, Brooke D Rakai, et al.
Translational Neuroscience|January 15, 2024
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammationSylwia Wasiak, Li Fu, Emily Daze, et al.
Pageof 4